Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMG1 | Q96Q15 | 8/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080481 | 0.84 | PRKDC (0.50) | PRKDCGAA | |
| SCHEMBL21217063 | 0.84 | PRKDC (0.52) | PRKDCGAASMG1LRRK2CSNK1D | |
| SCHEMBL3080598 | 0.81 | PRKDC (0.49) | PRKDCGAASMG1LRRK2CSNK1D | |
| SCHEMBL3081756 | 0.77 | PIK3CA (0.57) | PRKDCCSNK1DCSNK1EPIK3CAMAPT | |
| SCHEMBL3082054 | 0.74 | USP7 (0.41) | GAACSNK1DCSNK1ECDK2MAPT | |
| SCHEMBL3084111 | 0.74 | HSP90AA1 (0.44) | GAAMAPTSMN1; SMN2HTT | |
| SCHEMBL3081815 | 0.73 | CNR2 (0.47) | — | |
| SCHEMBL21208130 | 0.72 | CDK2 (0.48) | GAACDK2MAPTSMN1; SMN2HTT | |
| SCHEMBL28570789 | 0.72 | HSP90AA1 (0.47) | GAAMAPTSMN1; SMN2HTT | |
| SCHEMBL3080789 | 0.71 | FYN (0.48) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227880-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-09-09 | — | — | US | disclosed |
| EP-1984375-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007087548-A9 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007087548-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227880-A1 | CHEMICAL COMPOUNDS | CYP3A5, SLC10A1, ABCB11 | PRKDC 4406/4885GAA 196/4885SMG1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.